Publications

Student authors underlined

Prus AJ, Van Fossen MT, Iannucci AN, Dalton AG,  and Prete, J. N. (2024). Discriminative stimulus properties of two training doses of gabapentin in rats: Substitution by pregabalin, diazepam, and pentobarbital. Experimental and Clinical Psychopharmacology. Advance online publication. https://doi.org/10.1037/pha0000704 For a general audience overview, click here.

Park M and Prus AJ (2023). Lack of sex and estrous stage effects on compulsive behavior assessed using a schedule-induced polydipsia procedure in rats. Behavioural Pharmacology, 34, 236-244. http://dx.doi.org/10.1097/FBP.0000000000000723 

Lynch CJ and Prus AJ (2021). Assessment of antidepressant-like effects of dextromethorphan on differential reinforcement of low rate 72 second performance in rats. Behavioural Pharmacology, 32, 549-560. DOI: 10.1097/FBP.0000000000000649

Carey LM, Rice RJ, and Prus AP (2017). The neurotensin NTS1 receptor agonist PD149163 produces antidepressant-like effects in the forced swim test: Further support for neurotensin as a novel pharmacologic strategy for antidepressant drugs. Drug Development Research, 78, 196-202. DOI: 10.1002/ddr.21393

Steele III FF, Whitehouse SC, Aday JS, and Prus AJ (2017) Neurotensin NTS1 and NTS2 receptor agonists produce anxiolytic-like effects in the 22-kHz ultrasonic vocalization model in rats. Brain Research, 1658, 31-35. http://dx.doi.org/10.1016/j.brainres.2017.01.012

Prus AJ, Mooney-Leber SM, Berquist II MD, Pehrson AL, Porter HP, and Porter JH (2015) The antidepressant drugs fluoxetine and duloxetine produce anxiolytic-like effects in a schedule-induced polydipsia paradigm in rats: enhancement of fluoxetine’s effects by the α2 adrenoceptor antagonist yohimbine. Behavioural Pharmacology, 26, 489-494.

Hillhouse TM, Shankland Z, Matazel KS, Keiser AA, and Prus AJ (2014) The quetiapine active metabolite N-Desalkylquetiapine and the neurotensin NTS1 receptor agonist PD149163 exhibit antidepressant-like effects on operant responding in male rats. Experimental and Clinical Psychopharmacology, 22, 548-556.

Keiser AA, Matazel KS, Esser MK, Feifel D, and Prus AJ (2014) Systemic administration of the neurotensin NTS1receptor agonist PD149163 improves performance on a memory task in naturally deficient male Brown Norway rats.  Experimental and Clinical Psychopharmacology, 22, 541-547.

Prus AJ, Schuck CJ, Rusch KR, and Carey LM (2014)  The discriminative stimulus effects of the neurotensin NTS1receptor agonist PD149163 in rats:  Stimulus generalization testing with dopamine D1 and D2 receptor ligands.  Drug Development Research, 75, 47-58

Prus AJ, Hillhouse TM, and LaCrosse AL (2014) Acute, but not repeated, administration of the neurotensin NTS1receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.  Progress in Neuro-Psychopharmacology & Biological Psychiatry, 49, 78-84

Hillhouse, TM and Prus AJ (2013) Effects of the neurotensin NTS1 receptor agonist PD149163 on visual signal detection in rats.  European Journal of Pharmacology, 721, 201-207

Berquist II MD, Mooney-Leber SM, Feifel D, Prus AJ (2013) Assessment of attention in male and female Brattleboro rats using a self-paced five-choice serial reaction time task. Brain Research, 1537, 174-179

Holly EN, Ebrecht B, and Prus AJ  (2011) The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats. European Neuropsychopharmacology, 21, 526-531

Jacobson SM and Prus AJ (2010).  Evaluation of the effects of α2 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats.  Behavioural Pharmacology, 21, 654-659

Prus AJ, Zornio PA, Schuck CJ, Heerts T, Jacobson SM and Winiarski DA (2010). The discriminative stimulus properties of idazoxan: mediation by both α2 adrenoceptor antagonism and 5-HT1A receptor agonism. Drug Development Research, 71, 261-267

Prus AJ, Maxwell AT, Baker KM, Rosecrans JA, and James JR (2007). Acute behavioral tolerance to nicotine in the conditioned taste aversion paradigm. Drug Development Research, 68, 522-528